Metabolic pathway of exogenous and endogenous lipoproteins

Metabolic pathway of exogenous and endogenous lipoproteins. The exogenous pathway involves trafficking of dietary lipids to peripheral organs, and ultimately to the liver. Long chain fatty acids derived from hydrolyzed dietary lipids are transformed to triglyceride (TG) in lymphatic endothelial cells, and are packaged with, apolipoprotein B-48 (ApoB-48) as well as apolipoprotein E (ApoE) and apolipoprotein C (ApoC) to form chylomicrons. Chylomicrons secreted into intestinal lymphatic circulation reach systemic circulation via thoracic duct. Chylomicrons are hydrolyzed by lipoprotein lipase (LPL) that is anchored on the surface of capillary endothelium in adipose tissue, and heart and skeletal muscles to release free fatty acids (FFAs), and shrink to chylomicron remnants. Chylomicron remnants bind to low-density lipoprotein receptor (LDLR) thorough ApoE-mediated mechanism, and are rapidly cleared from the circulation. The endogenous pathway delivers hepatically derived lipoproteins to the periphery, providing energy source during fasting. Hepatocytes esterify fatty acids to form TG, which are packaged into very low-density lipoprotein (VLDL) particles with apoB-100. Circulating VLDL particles are hydrolyzed by LPL to release FFAs, and are referred to as intermediate-density lipoprotein (IDL). About 50% of IDL particles are removed by hepatocytes via ApoE-mediated binding to LDLR. The remainder of IDL particles are further processed by hepatic lipase (HL) to form low-density lipoprotein (LDL) particles. LDL particles may be removed from the circulation by hepatocytes via apoB-100-mediated binding to LDLR, or may serve as a source of cholesterol deposit in the peripheral tissue, triggering a subsequent atherosclerotic process
Metabolic pathway of exogenous and endogenous lipoproteins

Publication

Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview (2023) Sang Heon Suh, et al. Diabetes Metab J. 2023 Sep;47(5). Figure: F1.

Gene mentions


Organism Group Word Match Source NCBI Symbol NCBI ID
Homo sapiens Primates Small SMA2 ncbigene_synonym SMN1 6606
Homo sapiens Primates ApoE APOE ncbigene_symbol APOE 348
Homo sapiens Primates ApoB-48 APOB-48 ncbigene_synonym APOB 338
Homo sapiens Primates LDLR LDLR ncbigene_symbol LDLR 3949
Homo sapiens Primates LPL LPL ncbigene_symbol LPL 4023
Homo sapiens Primates LPL LPL ncbigene_synonym LCP1 3936

Chemical mentions

Word Match MeSH Name ChEBI
LDL LDL chebi:39026
VLDL VLDL chebi:39027
FFA FFA 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid chebi:42638
LDL LDL chebi:39026
LDL LDL chebi:39026
IDL IDL chebi:132933
FFA FFA 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid chebi:42638

Disease mentions

Word Match MeSH Name DOID